Remodulin

The recommended dose of Remodulin (Treprostinil) will vary on an individual basis. Remodulin (Treprostinil) is given either under the skin (subcutaneously) or into the vein (intravenously). It is given as a continuous infusion, which means that the medication will be flowing into your body on a constant basis. A health care provider will decide which route is best for you to receive the medication.

If you are being given Remodulin (Treprostinil) intravenously, you will need to have a special device inserted into your vein for the medication to be given (called a central venous catheter).

If you are being given Remodulin (Treprostinil) subcutaneously, you will need to have a self-inserted catheter (tube) placed under your skin. Both of these methods will require the use of a special pump that will help deliver the medication into your vein. A health care professional will teach you (and your caregiver or family member) how to prepare the medication and how to use the pump.

Your doctor will monitor your response to the medication and may adjust the dose of based on how you respond. A health care provider will teach you how to change your dose when and if it is necessary.

Many things can affect the dose of medication that a person needs, such as body weight, other medical conditions, and other medications. If your doctor has recommended a dose different from the ones listed here, do not change the way that you are using the medication without consulting your doctor.

It is important to use Remodulin (Treprostinil) exactly as recommended by your doctor. If your infusion of Remodulin (Treprostinil) is interrupted for any reason, contact your doctor to discuss what you should do.

Undiluted (unmixed) Remodulin (Treprostinil) that has been transferred into a syringe can be used for up to 72 hours. Remodulin (Treprostinil) that has been mixed with other solutions (such as normal saline or sterile water for injection) can be used for up to 48 hours after it has been mixed.

A single vial of Remodulin (Treprostinil) should not be used for more than 30 days after the first time you punctured the vial. If you notice that the vial of Remodulin (Treprostinil) contains a liquid that is hazy, contains particles, or has leaks, you should not use that vial and discard it.

Store Remodulin (Treprostinil) at room temperature (between 15°C to 30°C) and keep it out of the reach of children.

Do not dispose of medications in wastewater (e.g. down the sink or in the toilet) or in household garbage. Ask your pharmacist how to dispose of medications that are no longer needed or have expired.

1 mg/mL
Each mL of Remodulin Injection, 1 mg/mL, contains 1 mg of Remodulin (Treprostinil) (as Remodulin (Treprostinil) sodium). Nonmedicinal ingredients: sodium citrate, sodium chloride, metacresol, sodium hydroxide, and water for injection. Hydrochloric acid and sodium hydroxide may have been added to adjust pH.

2.5 mg/mL
Each mL of Remodulin Injection, 2.5 mg/mL, contains 2.5 mg of Remodulin (Treprostinil) (as Remodulin (Treprostinil) sodium). Nonmedicinal ingredients: sodium citrate, sodium chloride, metacresol, sodium hydroxide, and water for injection. Hydrochloric acid and sodium hydroxide may have been added to adjust pH.

5 mg/mL
Each mL of Remodulin Injection, 5 mg/mL, contains 5 mg of Remodulin (Treprostinil) (as Remodulin (Treprostinil) sodium). Nonmedicinal ingredients: sodium citrate, sodium chloride, metacresol, sodium hydroxide, and water for injection. Hydrochloric acid and sodium hydroxide may have been added to adjust pH.

10 mg/mL
Each mL of Remodulin Injection, 10 mg/mL, contains 10 mg of Remodulin (Treprostinil) (as Remodulin (Treprostinil) sodium). Nonmedicinal ingredients: sodium citrate, sodium chloride, metacresol, sodium hydroxide, and water for injection. Hydrochloric acid and sodium hydroxide may have been added to adjust pH.

Do not use Remodulin (Treprostinil) if you are allergic to Remodulin (Treprostinil), any medications with a similar chemical structure to the medication, or any ingredients of the medication.

There may be an interaction between Remodulin (Treprostinil) and any of the following:

• acetylsalicylic acid (Asa)
• alcohol
• Alfuzosin
• alpha agonists (e.g., Clonidine, methyldopa)
• angiotensin converting enzyme inhibitors (ACEIs; Captopril, Ramipril)
• angiotensin receptor blockers (ARBs; e.g., Candesartan, Irbesartan, Losartan)
• antiarrhythmics (e.g., Amiodarone, Dipyridamole, Disopyramide, Flecainide, procainamide, quinidine)
• anti-psychotics (e.g., Chlorpromazine, Clozapine, Haloperidol, Olanzapine, Quetiapine, Risperidone)
• Apixaban
• beta-adrenergic blockers (e.g., Atenolol, Propranolol, Sotalol)
• calcium channel blockers (e.g., Amlodipine, Diltiazem, Nifedipine, Verapamil)
• Celecoxib
• chloroquine
• dabigatran
• diuretics (water pills; e.g., Furosemide, Hydrochlorothiazide, triamterene)
• Domperidone
• Edoxaban
• Gemfibrozil
• Heparin
• herbal products that affect blood clotting (e.g., cat's claw, chamomile, fenugreek, evening primrose, feverfew, garlic, ginger, ginseng, turmeric)
• Hydralazine
• low molecular weight heparins (e.g., Dalteparin, Enoxaparin, Tinzaparin)
• macrolide antibiotics (e.g., clarithromycin, erythromycin)
• Methadone
• mifepristone
• nitrates (e.g., isosorbide dinitrate, Nitroglycerin)
• non-steroidal anti-inflammatory medications (NSAIDs; e.g., Diclofenac, Ibuprofen, Naproxen)
• Phenytoin
• Prasugrel
• primidone
• protein kinase inhibitors (e.g., Lapatinib, Pazopanib, Sunitinib)
• quinine
• quinolone antibiotics (e.g., ciprofloxacin, Ofloxacin,
• ritonavir
• saquinavir
• selective serotonin reuptake inhibitors (SSRIs; e.g., Citalopram, Fluoxetine, Paroxetine, Sertraline)
• serotonin antagonists (anti-emetic medications; e.g., Granisetron, Ondansetron)
• serotonin-norepinephrine reuptake inhibitors (SNRIs; Desvenlafaxine, Duloxetine, Venlafaxine)
• Tetrabenazine
• Warfarin

If you are taking any of these medications, speak with your doctor or pharmacist. Depending on your specific circumstances, your doctor may want you to:

• stop taking one of the medications,
• change one of the medications to another,
• change how you are taking one or both of the medications, or
• leave everything as is.

An interaction between two medications does not always mean that you must stop taking one of them. Speak to your doctor about how any drug interactions are being managed or should be managed.

Medications other than those listed above may interact with Remodulin (Treprostinil). Tell your doctor or prescriber about all prescription, over-the-counter (non-prescription), and herbal medications you are taking. Also tell them about any supplements you take. Since caffeine, alcohol, the Nicotine from cigarettes, or street drugs can affect the action of many medications, you should let your prescriber know if you use them.

Before you begin using a medication, be sure to inform your doctor of any medical conditions or Allergies you may have, any medications you are taking, whether you are pregnant or breast-feeding, and any other significant facts about your health. These factors may affect how you should use Remodulin (Treprostinil).

Infection: Since Remodulin (Treprostinil) is given intravenously and usually for a long period of time through a central venous catheter, this increases your risk of infections in the blood, which can be fatal.

If you notice any signs or symptoms such as a sudden onset of fever, fatigue, or headache, contact your doctor immediately. Giving the medication intravenously also puts you at increased risk of infections at the infusion site. Contact your doctor as soon as possible if you notice symptoms such as redness, tenderness, swelling, or pus at the infusion site.

Kidney or liver disease: If you have kidney or liver disease, discuss with your doctor how Remodulin (Treprostinil) may affect your medical condition, how your medical condition may affect the dosing and effectiveness of Remodulin (Treprostinil), and whether any special monitoring is needed.

Stopping the medication: Stopping Remodulin (Treprostinil) abruptly or sudden large decreases in the dose can result in symptoms of pulmonary hypertension such as pain when breathing (dyspnea), dizziness, weakness, and fatigue. If your Remodulin (Treprostinil) is stopped abruptly for some reason and you develop these symptoms, contact your doctor immediately.

Pregnancy: Remodulin (Treprostinil) should not be used during pregnancy unless the benefits outweigh the risks. If you become pregnant while taking Remodulin (Treprostinil), contact your doctor immediately.

Breast-feeding: It is not known if Remodulin (Treprostinil) passes into breast milk. If you are a breast-feeding mother and are taking Remodulin (Treprostinil), it may affect your baby. Talk to your doctor about whether you should continue breast-feeding.

Children: The safety and effectiveness of using Remodulin (Treprostinil) have not been established for children under 16 years of age.

Seniors: The safety and effectiveness of using Remodulin (Treprostinil) have not been established for people above 65 years of age.